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Abstract 
Translational research is a new and important way of thinking about research. It is a 
major priority of the National Institutes of Health (NIH) in the United States. NIH has 
created the Clinical and Translational Science Awards to promote this priority. NIH has 
defined T1 and T2 phases of translational research in the medical field, in order to bring 
the benefits of scientific results into communities. Current discussions focus on clarifying 
the subsequent phases of translational research necessary to achieve the intended social 
impact of research. This article suggests that T3 translational research could aim at 
getting research out of the highly controlled environment of the academic health center 
and into the real world. Likewise, it suggests T4 translational research could aim at policy 
development through policy analysis and evaluation, cost-benefit analysis, and 
surveillance studies. Translational research has challenges beyond definitions. 
Translational research is incomplete at any level unless appropriate steps are taken to 
communicate the results to relevant stakeholders. It appears that communication is 
currently suboptimal at all levels of translation. Translational research also faced 
challenges in research funding and training of researchers. Translational thinking should 
be a key part of research policy and research practice at all levels. 
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1. Current Thinking 
Translational research, at its core, builds on previous research to create broader 
applications of science, ultimately reaching the general public, finding general acceptance 
and influencing public policy decisions. It brings basic science out of the lab and creates 
practical advances for the good of society. Since translational research originated in 
medicine, and the author is in this field, this article is written in the context of medicine, 
but the concepts herein are widely applicable. Translational research is an important way 
of thinking for all investigators. (In this article, the author uses the term translational 
research. The term translational science can also be found in the literature. The two 
terms should be considered interchangeable.) 
The concept of translational research started with the National Institutes of Health (NIH), 
United States, but has implications across all disciplines. NIH created the idea of 
translational research with the formation of the Clinical and Translational Science 
Awards. NIH explains: 
Under NCATS’ leadership, the Clinical and Translational Science Awards 
(CTSA) Program supports a national network of medical research 
institutions—called hubs―that work together to improve the translational 
research process to get more treatments to more patients more quickly. The 
hubs collaborate locally and regionally to catalyze innovation in training, 
research tools and processes. 
CTSA Program support enables research teams including scientists, patient 
advocacy organizations and community members to tackle system-wide 
scientific and operational problems in clinical and translational research that 
no one team can overcome. Program goals are to: 
• Train and cultivate the translational science workforce; 
• Engage patients and communities in every phase of the translational process; 
• Promote the integration of special and underserved populations in translational 
research across the human lifespan; 
• Innovate processes to increase the quality and efficiency of translational 
research, particularly of multisite trials; and 
• Advance the use of cutting-edge informatics. 
(“About the CTSA Program,” 2016) 
The need for this approach is self-evident. Westfall, Mold, and Fagnan (2007) have 
estimated that, in the medical field, it takes 17 years for 14% of new scientific discoveries 
to enter routine clinical practice. In a study over a 15-year period, Contopoulos-Ioannidis, 
Ntzani, and Ioannidis (2003) showed that only 5% of “highly promising” basic science 
was licensed for clinical use and only 1% was actually used for the licensed therapeutic 
or preventive intervention. Dougherty and Conway (2008), Khoury et al. (2007), Szilagyi 
(2009) and Westfall, Mold, and Fagnan (2007) have made detailed arguments about how 
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few scientific advances are finding their way into improving the health of individuals and 
the general population; these arguments won’t be repeated here. 
NIH created definitions for T1 and T2 phases of translational research in 2004 with 
the NIH Roadmap for Medical Research (National Institutes of Health, 2008). T1 is 
defined as the translation of research from “bench to bedside.” It involves taking research 
from the laboratory and applying it to treatment of patients, often through clinical trials, 
and experimental procedures. T1 is usually the first application of a treatment to 
humans. T2 is the translation of research from “bedside to practice,” where T1 research 
has demonstrated efficacy in a controlled and limited trial, and it is being tested in a 
broader, but still highly controlled environment, such as an academic health center. 
There has since been an effort to build on the NIH framework for translational research. 
Westfall, Mold, and Fagnan (2007) suggested a T3 phase of translational research 
focused on day-to-day clinical practice, done in an ambulatory care setting or doctor’s 
office, where patients receive most of their care. Dougherty and Conway (2008) 
expanded this definition, suggesting an ever broader base for T3, which includes “policy 
changes necessary to foster attempts to improve health outcomes” (p. 2319). Szilagyi 
(2009) extended the phases of translational research to include T4, which encompasses 
the policy level. Both Khoury et al. (2007) and Khoury, Gwinn, and Ioannidis (2010) also 
suggested T4, focused on the translation of research from clinical practice to population 
health impact, including policy development. 
The purpose of this article is to advance the discussion by suggesting a definition 
of T3 and T4 within the framework of T1 and T2, using some real, illustrative examples. 
In addition, the article discusses some of the challenges and barriers associated with 
translational research. All of this is done to help reach consensus and move forward 
toward the goal of translational research: bringing scientific results into communities. 
2. T3 and T4 Translational Research: Proposed Definitions and Examples 
T1 and T2 translational research brings scientific discoveries out of the laboratory and 
into clinical practice, but not fully into the real world. T3 translational research takes the 
next step and brings research into communities in order to test if the new treatments and 
interventions based on scientific research would work in less controlled 
conditions. T4 takes this process forward to determine if the research can benefit 
communities through appropriate public health policies and programs. This finds 
resonance in the work of Khoury, Gwinn, and Ioannidis (2010) who indicate the 
importance of epidemiology to translational research, drawing attention to the public 
health dimension of medical research. Accordingly, the author proposes the following 
definitions of the T3 and T4 phases of translational research. 
2.1. Proposed Definitions of T3 and T4 Translational Research 
T3: Practice to Community. T3 research moves out of the controlled environment (e.g., 
an academic health center) and into the community—the real world—where it is subject 
to random and uncontrollable effects. T3 often involves strategies and interventions 
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which were successful on a small scale in a controlled environment and determines if 
these can be scaled up to a larger population, being implemented in primary care 
practices, ambulatory care centers, and community clinics. Examples of T3 research 
includes community-based participatory research (CBPR) and Phase IV clinical trials. 
Israel, Schulz, Parker, and Becker (1998) define CBPR is a partnership approach to 
research that involves community members, organizational representatives, and 
researchers equitably in all aspects of the research process and in which all partners 
contribute expertise and share decision making and ownership. The aim of CBPR is to 
increase knowledge of a given phenomenon and integrate the knowledge gained with 
interventions and policy to improve the quality of life of community members. 
Phase IV clinical trials are done after the drug or treatment has been marketed to gather 
information on the drug’s effect in various populations and any side effects associated 
with long-term use. 
T4: Community to Public Health. T4 research evaluates the implementation and efficacy 
of policies and accepted medical practices, as they impact individual and public health 
outcomes. T4 research may include cost–benefit analysis, policy analysis, surveillance 
studies, and program evaluation. 
2.2. Examples of T3 and T4 Translational Research 
2.2.1. Vaccine Development 
Vaccine development is an excellent example of the effective implementation of 
translational research. At the T1 level, basic research is conducted to determine if a 
vaccine can be created. This is done in the laboratory, with animals and limited human 
trials. At the T2 level, highly controlled trials are run to determine both the safety and 
efficacy of the vaccine. At the T3 level, in the United States, the US Food and Drug 
Administration (FDA) authorizes the general use of the vaccine. FDA and US Centers for 
Disease Control and Prevention (CDC) would monitor adverse reactions through their 
existing reporting system. CDC would track the progression of disease to evaluate the 
community-wide efficacy of the vaccine. Finally, CDC’s Advisory Committee on 
Immunization Practices (ACIP) would evaluate data and create a policy for use in clinical 
and community settings. The vaccine may be recommended for use within a set 
immunization schedule or suggested as optional. 
ACIP, FDA, and CDC continuously monitor effectiveness of the vaccine as well as its 
adverse reactions, if any. This is T4 translational research. At all levels, scientific results 
are communicated through existing networks, from FDA announcements, scholarly 
journals, Morbidity and Mortality Weekly Review, and press releases to the general 
public. Such pronouncements receive wide publicity in the general news media. 
Weinberg and Szilagyi (2010) have also explained T1-T4 phases of translational research 
using a vaccine example, specifically the rotavirus vaccine. 
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2.2.2. Drug Development 
Drug development is another example. There has been substantial progress in treating 
certain types of leukemia, especially Chronic Lymphocytic Leukemia (CLL). Basic 
science found that kinase (enzymes that catalyze certain cellular processes) played a role 
in the proliferation and survival of abnormal white blood cells (leukemia cells). At 
the T1 level, research was done to determine the mechanism of this reaction and 
investigate drugs to inhibit kinase to stop the reaction. Existing drugs used to treat 
leukemia were not very effective with this disease. At the T2 level, Eichhorst et al. (2013) 
showed that existing drugs used to treat CLL had toxic effects on older people. Phase III 
studies by Goede et al. (Goede, Fischer, Busch et al., 2014; Goede, Fischer, Engelke et 
al., 2015) and Hillmen et al. (2015) showed that the addition of drugs related to ibrutinib 
to existing therapies showed improvement in reduction of disease progression and patient 
survival. Bringing all these results together at the T3 level, 269 patients over 65 years old 
were treated with ibrutinib as a frontline drug. Burger et al. (2015) reported that 90% 
were progression free at the 18-month endpoint, with minimal adverse reactions. 
Research showed that ibrutinib could inhibit kinase in this environment. T3 Research 
continues to determine the long term efficacy of this drug—84% of the patients in the 
trial are still alive and the disease has not progressed in this group. T4 research now 
continues to investigate the efficacy of ibrutinib and other similar drugs to inhibit CLL 
and other cancers. Finally, there is thinking that some forms of cancer are indeed chronic 
diseases. T4 research will assess the correctness of this thinking, if ibrutinib is effective in 
prolonging their survival indefinitely. This would change people’s perception of cancer, 
in general, and specifically CLL/leukemia, encouraging people to think of this as just 
another chronic disease for which they should be screened. 
2.2.3. Influenza Prevention 
A third example to illustrate T3 and T4 translational research comes from public health. 
The Pittsburgh Influenza Prevention Project (PIPP) was a prospective, controlled, cluster-
randomized design to test the effectiveness of a suite of multi-layered, non-
pharmaceutical interventions (NPIs) in controlling influenza in elementary schools. At 
the T1 level, it is now accepted as fact that soap and alcohol based hand sanitizers kill 
germs. Stebbins, Stark, and Vukotich (2010) found six T2 studies that demonstrated 
school children could adopt NPIs and obtain a positive outcome. PIPP built on 
the T2 studies and created a large scale NPI intervention, a T3 translation. Stebbins, 
Cummings et al. (2011) found that the intervention was effective in reducing influenza A 
by 52% and absenteeism by 26%. PIPP extended this research into T4 by disseminating 
the results to schools in the region for the NPIs to be adopted as school-wide policy. The 
full implementation of a T4 research effort would have included the evaluation of schools 
adopting the intervention policy, but PIPP was not able to do this fully. 
3. Challenges of Translational Research 
While the first challenge is to come to a widespread agreement on what translation 
research is, there are additional issues which must be addressed before the research 
community can become more successful in bringing the benefits of research to the world. 
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In order for research to be useful, its results and implications must be communicated to 
potential users. The T1 and T2 phases may be the easiest in this regard. T1 and T2 are 
reported in peer-reviewed journals, which are readily accessed by investigators 
monitoring the literature. T1 and T2 research may be well documented through 
conference presentations and other collegial interactions. T1 and T2 research are often 
shared with colleagues who are working at the same academic medical center. But, even 
here, all presupposed communication does not occur. Szilagyi (2009) found that many 
factors hinder communication, including “research silos,” a desire to prolong studies to 
maintain funding, and regulatory obstacles. Finally, communication does not ensure use. 
Community-based practitioners do not have the time, inclination, or resources to monitor 
this peer-reviewed literature. Community and government leaders do not read the medical 
literature, and they are not colleagues of those doing the investigations. The people who 
might use research do not attend the same conferences as the researchers. 
In a survey of 292 policymakers by Sorian and Baugh (2002), 89% said that they want to 
know what the researcher sees as the policy implications or recommendations. These 
authors quoted one respondent as characteristic of the general sentiment: “I may not 
follow the researcher’s advice, but I want to know what they think” (Sorian & Baugh, 
2002, p. 271). 
Mirvis (2009) examined the extent to which research findings, both basic and clinical, are 
applied to design public policies that promote health. He concluded that, in spite of the 
desire, and the obvious value of data-driven policy making, research is not commonly 
used in setting policy. Kon (2008) also made a similar observation and emphasized the 
importance of communication. 
Feinstein (1999) suggested that there is also much less written at the T3 and T4 levels, as 
most funding is focused on the basic science level. Szilagyi (2009) found that more than 
90% of funding is focused on T1 research, although it is difficult to determine the exact 
amount of funding, since funding is not categorized that way. He concluded that very 
little research funding has a T3 or T4 focus. 
Writing on the mission of the journal Clinical and Translational Science, Feldman (2008) 
identified another problem. He suggested that translational research requires a 
multidisciplinary approach, but there is a “paucity of well-trained multi- and inter-
disciplinary investigative teams” (p. 1) that limits the ability to apply new knowledge. 
Accordingly, the academic community should be educating scientists on the principles of 
translational research. The author has found little evidence of this. With the importance of 
NIH in the medical community, medical schools should be at the forefront. Feldman 
(2015) congratulated the Association of American Medical Colleges (AAMC) that it has 
included translational research instruction into its accreditation standards. However, he 
cites that this is “[u]nrecognized by most translational scientists and by leaders of clinical 
and translational science institutes” (p. 267).  In addition, “the AAMC has left it up to 
individual schools of medicine to create the programs that will provide students with the 
requisite experience in CTS [clinical and translational research]” (p. 268). He concludes 
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that there is an important need to create a standard curriculum on clinical and 
translational research. 
4. Discussion and Conclusions 
It is obvious that the translation of research into practical applications is important. The 
effort to define translational research may seem pedantic, but it is important for 
investigators to consider how their work could advance to the next step of research 
application. Thus, it is important that we consider the subject of translational research so 
that we make it a part of the entire research process, not just an afterthought. 
This article has focused on defining translational research as four distinctive nodes, T1-
T2-T3-T4. Others suggest more complex models. Dougherty and Conway (2008), Khoury 
et al. (2007), and Szilagyi (2009) suggest that it is a continuum. Mata and Davis (2012) 
have suggested that translational research involves a complex feedback loop. This is a 
matter for future consideration and refinement of translational research thinking and 
practice. 
The scientific community also needs to consider how to promote translational research. 
Communication with multiple stakeholders is critical. Scientific work is usually 
disseminated in peer-reviewed journals, without regard to who might see it. Translational 
research directs us to disseminate our scientific research to those in a position to do 
additional research, utilize it in practice or community, make policy which can affect 
public health, and use it to make personal health decisions. But professional journals can 
be silos in which those outside the field are not engaged. We have to begin to consider 
how to break down barriers to the flow of knowledge beyond our own disciplines. 
Investigators should be thinking of the applicability of their research and how the results 
will be communicated, as part of their overall project design. Funders and Institutional 
Review Boards could make this a formal part of their process. 
Finally, translational research should be part of the education and development of all 
researchers. It is hoped that increased recognition of the breadth and depth of 
translational research will lead to more funding and development of T3 and T4 
translational research. 
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